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The UK Clinical and Translational Radiotherapy Research Working Group (CTRad) was 
established in 2009 by The National Cancer Research Institute (NCRI) and its funding partners, 
in response to reviews of the radiotherapy research landscape in 20031 and 20082, which had 
identified radiation biology and oncology as areas of unmet need. At the launch, CTRad’s 
inaugural chair, Professor Tim Maughan, announced a 10-point plan to tackle the challenges 
identified in the reviews while capitalising on opportunities for progress.2   
 
In 2019 we celebrate CTRad’s 10th anniversary and illustrate the progress made by the UK 
radiotherapy research community by describing CTRad’s ‘Top 10’ achievements.3 
 
1. Development of a broad portfolio of radiotherapy trials 
Developing innovative, impactful radiotherapy clinical trials has always been CTRad’s primary 
function. We have overseen the development of a broad portfolio of radiotherapy-focused 
trials, including early and late phase studies evaluating intensity modulated (IMRT), 
stereotactic ablative (SABR) and molecular radiotherapy (MRT). To achieve this, CTRad 
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created a pipeline that features Clinical Trials Workshops, aimed at junior researchers, Trials 
Sandpit Events and biannual Clinical Trials Proposals Guidance Meetings that are attended by 
most CTRad members. These meetings have educated, challenged and supported research 
teams progressing from concept through development to funding and recruitment. Between 
2009 and 2018, 231 study proposals have been presented, of which 71 have been funded. 
 
2. Spearheading innovative clinical trial design 
Responding to the increasingly competitive funding environment and recognising the 
limitations of traditional clinical trial designs, CTRad has encouraged researchers to develop 
more innovative and collaborative approaches. A prime example is the recently funded 
CONCORDE trial4: a randomised, phase I platform study evaluating five different inhibitors of 
the DNA damage response in combination with radical radiotherapy for non-small cell lung 
cancer (NSCLC). As well as bringing together researchers from multiple UK centres, 
CONCORDE represents effective partnership with the pharmaceutical industry. Other 
innovative trials include PATHOSi (de-intensification of treatment for human papillomavirus 
driven head and neck cancer), PLATO ii  (phase II-III platform study in anal cancer), 
PIVOTALboost iii  (pelvic node and prostate boost radiotherapy in prostate cancer) and 
PARADIGMiv (radiotherapy plus the PARP inhibitor olaparib in glioblastoma). CTRad convenes 
trial-specific workshops at which researchers from diverse disciplines and NCRI Consumers 
refine study concepts and maximise translational content. 
 
3. Benchmarking radiotherapy research excellence  
                                                          
i https://clinicaltrials.gov/ct2/show/NCT02215265 
ii http://www.isrctn.com/ISRCTN88455282 
iii http://www.isrctn.com/ISRCTN80146950 
iv http://www.isrctn.com/ISRCTN52658296 
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Prior to CTRad, radiotherapy research had a low profile within the higher education and 
research funding communities and information about research activity in UK centres was 
lacking. To address this, CTRad undertook a world-leading ‘Centres of Excellence in Academic 
Radiation Oncology’ benchmarking exercise, which established categories of research activity 
and criteria of success then evaluated eighteen UK centres. Completed in 2016,5 the exercise 
received international attention and has profoundly influenced the aspirations and activities 
of researchers and funders. More recently, CTRad undertook a survey of UK Academic Medical 
Physics activity, identifying key strengths and weaknesses that will inform future work in this 
area.6 
 
4. Excellence in patient and public involvement (PPI) 
In keeping with NCRI policy placing patients at the heart of its activities, CTRad’s NCRI 
Consumers have provided innovative, high quality contributions at all stages of our strategic 
development, and in the development of individual studies. This engagement has helped the 
radiotherapy research community to maximise the quality and impact of its clinical trials. For 
example, CTRad’s NCRI Consumers have developed a range of resources for researchers, 
including guidance on writing a good lay summary, which is available online.7 
 
5. Engagement with funders and influencing policy 
An important barrier to the development of world class radiotherapy research programmes 
in the UK has been the relative paucity of funding. Although radiotherapy is received by 
approximately half of cancer patients, only 5% of cancer research funding has been directed 
at radiotherapy related projects. This can be attributed to the absence of specific funding 
schemes, poor representation of radiation researchers on funding committees, and lack of 
investment in infrastructure. To address this imbalance, CTRad has facilitated and influenced 
new funding schemes, notably the CRUK Radiation Research Network (RadNet) initiative,8 and 
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supported successful collaborative networks including CRUK ART-NET,9  STFC Global Challenge 
Network+,v EPSRC Grand Challenge Networkvi and EU INSPIRE.vii CTRad also worked with CRUK 
and NHS England to secure NHS support for radiotherapy costs for SABR trials. 
 
6. National and international leadership on radiotherapy-drug combinations  
Having identified a dearth of clinical trials evaluating novel radiotherapy-drug combinations, 
CTRad convened a multidisciplinary panel to identify causes and potential solutions, with 
particular emphasis on the route to registration for novel drugs in combination with 
radiotherapy. This work was captured in a ‘Consensus Statement’ published in Nature Reviews 
Clinical Oncology in 201610, which inspired an FDA sponsored workshop in Bethesda, USA that 
generated further published guidelines in 2018.11 This initiative has leveraged unprecedented 
international engagement, with input from the US Food and Drug Administration (FDA), 
European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory 
Authority (MHRA), US National Cancer Institute (NCI), American Association for Cancer 
Research (AACR) and American Society of Radiation Oncology (ASTRO). In the UK, CTRad 
created and leads the Radiotherapy-Drug Combinations Consortium (RaDCom) and 
established the UK NSCLC Radiotherapy-Drug Consortium, which has developed the 
CONCORDE and SPITFIRE studies.   
 
7. Building a multidisciplinary radiotherapy research workforce  
CTRad has worked with multiple stakeholders to support the establishment of a sustainable 
community of researchers that includes clinical oncologists, radiographers, medical physicists, 
statisticians, radiologists, laboratory scientists, medical oncologists, nuclear medicine 
physicians and consumers. Many of these disciplines lack established research communities 
                                                          
v https://www.advanced-radiotherapy.ac.uk 
vi http://protontherapynetwork.com 
vii https://protonsinspire.eu 
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or academic career pathways so we have engaged with relevant colleges and higher education 
institutes to support the evolution of successful research leaders and academic cohorts. In 
parallel, ‘Academic Think Tank’ events have been organised for clinicians, physicists and 
radiographers. Trainees are regularly involved in projects, making important contributions to 
our work investigating delays in opening trials. We encourage all individuals working within, 
or connected to, the UK radiotherapy community to become CTRad members; details are 
available on our website: http://ctrad.ncri.org.uk  
 
8. Supporting quality assurance for radiotherapy clinical trials  
Quality assurance is a fundamental component of radiotherapy research, particularly when 
new and complex technologies are being evaluated. In the UK, all National Institute for Health 
Research (NIHR) portfolio radiotherapy trials have access to the unique expertise and 
resources of the Radiotherapy Trials Quality Assurance (RTTQA) group, which receives core 
funding from the NIHR. CTRad has worked closely with RTTQA since its inception in 2010, 
playing important roles in governance and the development and delivery of scientific outputs. 
CTRad also undertook a comprehensive review of the national MRT landscape, its 2016 
report12 on which led to implementation of QA programmes creating a unique network of 
centres capable of standardised dosimetry for current and future MRT trials.  
 
9. Coordinating a national approach to proton beam therapy (PBT) trial development 
The CTRad PBT Strategy Group is a multidisciplinary, UK-wide group currently co-ordinating 
the development of PBT clinical trials in partnership with ART-NET.13 The opening of NHS 
England proton beam facilities in Manchester (2018) and London (2020) provided a unique 
opportunity to design and deliver high quality clinical trials that will determine the benefits to 
patients of PBT compared with photon-based treatments, across a range of adult tumour sites. 
This initiative convenes relevant disciplines to accelerate funding of the best clinical studies; 
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to date, three workshops have reviewed 10 PBT trials proposals, providing investigators with 
expert feedback. CRUK has funded the UK’s first PBT trial, the TORPEdO study in head and 
neck cancer, which was developed with CTRad’s guidance and strategic oversight. 
 
10. CTRad identified as NCRI’s flagship initiative 
Having been supported by multiple NCRI partners since its launch in 2009, CTRad was 
delighted to be described as the NCRI’s “flagship radiotherapy initiative” in its 2017-18 annual 
review. Illustrating this, CTRad has inspired the creation and design of new initiatives including 
the Cellular Molecular Pathology (CM-Path) programme that was launched in 2016. 
 
 
Summary 
 
Since 2009, CTRad has dramatically influenced the UK radiotherapy research landscape by 
championing multi-disciplinary radiotherapy research on a national scale. Significant 
challenges remain, however, including delivering the five pillars of CTRad’s new research 
strategy (Figure 1) and addressing the key scientific and clinical research questions identified 
in CRUK’s recent Strategic Review of radiotherapy research. 14  
 
While CRUK’s investment in RadNet is an important step forward, substantial further work is 
required to address underfunding of radiotherapy research across the UK as a whole. CTRad 
will play a pivotal role in addressing this issue, aiming to leverage investment across the full 
spectrum of funders while uniting the UK research community to improve outcomes for 
cancer patients.   
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Figure 1 CTRad's strategic vision, 2018–2021. 
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Appendix 1. CTRad Executive Group members (June 2019) 
 
David Sebag-Montefiore (Chair) 
Mererid Evans (Deputy Chair) 
Anthony Chalmers (Ex-officio) 
Gillies McKenna (Ex-officio)  
Elizabeth Miles (Ex-officio)  
Jonathan Wadsley (Ex-officio) 
Kaye Williams (Ex-officio) 
Richard Stephens (Consumer member) 
Nicola Curtin (Workstream 1) 
Ricky Sharma (Workstream 1)  
Richard Adams (Workstream 2)  
Ananya Choudhury (Workstream 2)  
Emma Hall (Workstream 3)  
Robert Huddart (Workstream 3)  
Karen Kirkby (Workstream 4)  
Maria Hawkins (Workstream 4)  
Carolyn Chan (NCRI)  
 
For more information and a list of members, please see the CTRad webpage 
(https://ctrad.ncri.org.uk).  
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Appendix 2. CTRad’s funding partners 
 
CTRad is funded by Cancer Research UK, the Medical Research Council, Chief Scientist Office 
Scotland, Health and Care Research Wales, HSC Public Health Agency Northern Ireland, Breast 
Cancer Now and Prostate Cancer UK. 
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